ArticleJournal of translational medicine2026
ATIC facilitates the malignant progression of bladder cancer by modulating AMPK-mTOR-S6K1 axis under folate reprogramming.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic reprogramming is a hallmark of cancer, yet the role of ATIC-mediated folate metabolism in bladder and other solid tumors remains understudied. Due to its critical role in cancer cell growth, folate metabolism could be a promising target for novel, broadly applicable cancer therapies.
methodsThis study integrated multiple bladder cancer datasets from TCGA, GEO, and clinical data from 80 patients at our hospital to explore the relationship between ATIC and folate metabolism. We focused on expression patterns, prognosis, metabolic processes, microenvironment, drug resistance, and associated pathways. Through multi-omics analysis, 97 single-cell datasets, 18 spatial tissue slices, and machine learning approaches, we assessed ATIC as a pan-cancer driver and identified key folate metabolism-related driver genes.
resultsWe found that ATIC overexpression in bladder cancer was linked to poor prognosis, GC chemotherapy resistance, elevated cancer folate levels, and malignant phenotypes. Our study first proposed that ATIC promotes bladder cancer progression by regulating the AMPK-mTOR-S6K1 axis under folate reprogramming. We also validated ATIC-folate reprogramming crosstalk across cancers through pan-cancer analysis and created a multi-cancer folate metabolism-driven gene map, highlighting the importance of ATIC and folate metabolism in future oncology research.
conclusionsOur study identifies ATIC as a key cancer driver gene. Targeting ATIC offers a promising therapeutic strategy, especially for bladder cancer and potentially other cancers with disrupted folate metabolism. These findings highlight new treatment possibilities targeting metabolic vulnerabilities in cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.